greeksoup/ stock research
Stock research / United States / NRIX / Documents

Nurix Therapeutics, Inc. documents

Nurix Therapeutics (NRIX) annual report: the 10-K filed 28 January 2026 for the year ended 30 November 2025. Proxy statement (DEF 14A) filed 27 March 2026; latest 10-Q filed 13 October 2026 for the quarter ended 31 August 2026. Each links to the document on EDGAR, with 4 earnings press releases.

Earnings press releases (exhibit 99 to each results 8-K)

FiledDocumentOpenWhere
13 October 2026Results press release, exhibit 99 to the 8-K filed 13 October 2026The releaseEDGAR folder
9 July 2026Results press release, exhibit 99 to the 8-K filed 9 July 2026The releaseEDGAR folder
8 April 2026Results press release, exhibit 99 to the 8-K filed 8 April 2026The releaseEDGAR folder
28 January 2026Results press release, exhibit 99 to the 8-K filed 28 January 2026The releaseEDGAR folder

Annual reports (10-K)

FiledDocumentOpenWhere
28 January 202610-K, period ended 30 November 2025The documentEDGAR folder

Quarterly reports (10-Q)

FiledDocumentOpenWhere
13 October 202610-Q, period ended 31 August 2026The documentEDGAR folder
9 July 202610-Q, period ended 31 May 2026The documentEDGAR folder
8 April 202610-Q, period ended 28 February 2026The documentEDGAR folder

Proxy statements

FiledDocumentOpenWhere
27 March 2026DEF 14A, period ended 15 May 2026The documentEDGAR folder

Annual report to shareholders

FiledDocumentOpenWhere
27 March 2026ARS, period ended 30 November 2025The documentEDGAR folder